These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 36695165)

  • 1. Mean corpuscular haemoglobin concentration and outcomes in heart failure with preserved ejection fraction.
    Choy M; Zhen Z; Dong B; Chen C; Dong Y; Liu C; Liang W; Xue R
    ESC Heart Fail; 2023 Apr; 10(2):1214-1221. PubMed ID: 36695165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interaction Between Spironolactone and Natriuretic Peptides in Patients With Heart Failure and Preserved Ejection Fraction: From the TOPCAT Trial.
    Anand IS; Claggett B; Liu J; Shah AM; Rector TS; Shah SJ; Desai AS; O'Meara E; Fleg JL; Pfeffer MA; Pitt B; Solomon SD
    JACC Heart Fail; 2017 Apr; 5(4):241-252. PubMed ID: 28359411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spironolactone in Patients With Heart Failure, Preserved Ejection Fraction, and Worsening Renal Function.
    Beldhuis IE; Myhre PL; Bristow M; Claggett B; Damman K; Fang JC; Fleg JL; McKinlay S; Lewis EF; O'Meara E; Pitt B; Shah SJ; Vardeny O; Voors AA; Pfeffer MA; Solomon SD; Desai AS
    J Am Coll Cardiol; 2021 Mar; 77(9):1211-1221. PubMed ID: 33663739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Visit-to-Visit Variability in Kidney Function and Serum Electrolyte Indexes With Risk of Adverse Clinical Outcomes Among Patients With Heart Failure With Preserved Ejection Fraction.
    Segar MW; Patel RB; Patel KV; Fudim M; DeVore AD; Martens P; Hedayati SS; Grodin JL; Tang WHW; Pandey A
    JAMA Cardiol; 2021 Jan; 6(1):68-77. PubMed ID: 33206129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Spironolactone in Patients With HFpEF and Chronic Kidney Disease.
    Beldhuis IE; Myhre PL; Claggett B; Damman K; Fang JC; Lewis EF; O'Meara E; Pitt B; Shah SJ; Voors AA; Pfeffer MA; Solomon SD; Desai AS
    JACC Heart Fail; 2019 Jan; 7(1):25-32. PubMed ID: 30606484
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prior Pacemaker Implantation and Clinical Outcomes in Patients With Heart Failure and Preserved Ejection Fraction.
    Shen L; Jhund PS; Docherty KF; Petrie MC; Anand IS; Carson PE; Desai AS; Granger CB; Komajda M; McKelvie RS; Pfeffer MA; Solomon SD; Swedberg K; Zile MR; McMurray JJV
    JACC Heart Fail; 2019 May; 7(5):418-427. PubMed ID: 30981744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic Importance of Temporal Changes in Resting Heart Rate in Heart Failure and Preserved Ejection Fraction: From the TOPCAT Study.
    Vazir A; Claggett B; Pitt B; Anand I; Sweitzer N; Fang J; Fleg J; Rouleau J; Shah S; Pfeffer MA; Solomon SD
    JACC Heart Fail; 2017 Nov; 5(11):782-791. PubMed ID: 29032132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Natriuretic Peptides With Cardiovascular Prognosis in Heart Failure With Preserved Ejection Fraction: Secondary Analysis of the TOPCAT Randomized Clinical Trial.
    Myhre PL; Vaduganathan M; Claggett BL; Anand IS; Sweitzer NK; Fang JC; O'Meara E; Shah SJ; Desai AS; Lewis EF; Rouleau J; Pitt B; Pfeffer MA; Solomon SD
    JAMA Cardiol; 2018 Oct; 3(10):1000-1005. PubMed ID: 30140899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Racial Differences in Characteristics and Outcomes of Patients With Heart Failure and Preserved Ejection Fraction in the Treatment of Preserved Cardiac Function Heart Failure Trial.
    Lewis EF; Claggett B; Shah AM; Liu J; Shah SJ; Anand I; O'Meara E; Sweitzer NK; Rouleau JL; Fang JC; Desai AS; Retta TM; Solomon SD; Heitner JF; Stamos TD; Boineau R; Pitt B; Pfeffer MA
    Circ Heart Fail; 2018 Mar; 11(3):e004457. PubMed ID: 29664406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The TOPCAT Trial.
    Cikes M; Claggett B; Shah AM; Desai AS; Lewis EF; Shah SJ; Anand IS; O'Meara E; Rouleau JL; Sweitzer NK; Fang JC; Saksena S; Pitt B; Pfeffer MA; Solomon SD
    JACC Heart Fail; 2018 Aug; 6(8):689-697. PubMed ID: 30007557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic impact of abnormal sodium burden in heart failure patients with preserved ejection fraction.
    Zhen Z; Choy M; Dong B; Dong Y; Liang W; Liu C; Xue R
    Eur J Clin Invest; 2024 Feb; 54(2):e14115. PubMed ID: 37877605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Leucocyte count predicts cardiovascular risk in heart failure with preserved ejection fraction: insights from TOPCAT Americas.
    Bajaj NS; Kalra R; Gupta K; Aryal S; Rajapreyar I; Lloyd SG; McConathy J; Shah SJ; Prabhu SD
    ESC Heart Fail; 2020 Aug; 7(4):1676-1687. PubMed ID: 32424980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Perturbations in serum chloride homeostasis in heart failure with preserved ejection fraction: insights from TOPCAT.
    Grodin JL; Testani JM; Pandey A; Sambandam K; Drazner MH; Fang JC; Tang WHW
    Eur J Heart Fail; 2018 Oct; 20(10):1436-1443. PubMed ID: 29893446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Physical Activity and Prognosis in the TOPCAT Trial (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist).
    Hegde SM; Claggett B; Shah AM; Lewis EF; Anand I; Shah SJ; Sweitzer NK; Fang JC; Pitt B; Pfeffer MA; Solomon SD
    Circulation; 2017 Sep; 136(11):982-992. PubMed ID: 28637881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular and Renal Outcomes of Mineralocorticoid Receptor Antagonist Use in PARAGON-HF.
    Jering KS; Zannad F; Claggett B; Mc Causland FR; Ferreira JP; Desai A; Barkoudah E; McMurray JJV; Pfeffer MA; Solomon SD
    JACC Heart Fail; 2021 Jan; 9(1):13-24. PubMed ID: 33189633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peripheral artery disease and risk of adverse outcomes in heart failure with preserved ejection fraction.
    Sandesara PB; Hammadah M; Samman-Tahhan A; Kelli HM; O'Neal WT
    Clin Cardiol; 2017 Sep; 40(9):692-696. PubMed ID: 28444995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes of patients with anemia and renal dysfunction in hospitalized heart failure with preserved ejection fraction (from the CN-HF registry).
    Jin X; Cao J; Zhou J; Wang Y; Han X; Song Y; Fan Y; Chen Z; Xu D; Yang X; Dong W; Li L; Chen L; Zhong Q; Fu M; Hu K; Zhou J; Ge J;
    Int J Cardiol Heart Vasc; 2019 Dec; 25():100415. PubMed ID: 31508483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiac Troponin I and Risk of Cardiac Events in Patients With Heart Failure and Preserved Ejection Fraction.
    Myhre PL; O'Meara E; Claggett BL; de Denus S; Jarolim P; Anand IS; Beldhuis IE; Fleg JL; Lewis E; Pitt B; Rouleau JL; Solomon SD; Pfeffer MA; Desai AS
    Circ Heart Fail; 2018 Nov; 11(11):e005312. PubMed ID: 30571192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic implications of plasma volume status estimates in heart failure with preserved ejection fraction: insights from TOPCAT.
    Grodin JL; Philips S; Mullens W; Nijst P; Martens P; Fang JC; Drazner MH; Tang WHW; Pandey A
    Eur J Heart Fail; 2019 May; 21(5):634-642. PubMed ID: 30714658
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of β-Blocker Use With Heart Failure Hospitalizations and Cardiovascular Disease Mortality Among Patients With Heart Failure With a Preserved Ejection Fraction: A Secondary Analysis of the TOPCAT Trial.
    Silverman DN; Plante TB; Infeld M; Callas PW; Juraschek SP; Dougherty GB; Meyer M
    JAMA Netw Open; 2019 Dec; 2(12):e1916598. PubMed ID: 31800067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.